ERX-963 / Expansion Therap - LARVOL DELTA

[VIRTUAL] Results of Double-blind, Placebo-controlled, Dose Range Finding, Crossover Study of Single Day Administration of ERX-963 (IV Flumazenil) in Adults with Myotonic Dystrophy Type 1 (AAN 2021) - "While ERX-963 at 1 mg and 2 mg was safe, there was no evidence of efficacy in measures of sleepiness or vigilance with this dose and administration regimen."

Clinical • CNS Disorders • Excessive Daytime Sleepiness • Myotonic Dystrophy • Obstructive Sleep Apnea • Sleep Apnea • Sleep Disorder

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Expansion Therapeutics, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders • Genetic Disorders • Muscular Atrophy • Myotonic Dystrophy

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: Expansion Therapeutics, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed